Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Report 2021

Publisher Name :
Date: 06-May-2021
No. of pages: 142
Inquire Before Buying

The global Benign Prostatic Hyperplasia (BPH) Medication market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia (BPH) Medication market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type

- 5-Alpha-Reductase Inhibitors

- Beta-Blockers

- Botanicals and Traditional Chinese Medicine

Segment by Application

- Hospital Pharmacies

- Retail Pharmacies

- Online Pharmacies

The Benign Prostatic Hyperplasia (BPH) Medication market is analysed and market size information is provided by regions (countries). Segment by Application, the Benign Prostatic Hyperplasia (BPH) Medication market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company

- Astellas Pharma

- Eli Lilly

- GlaxoSmithKline

- Sanofi

- ADC Therapeutics

- Bayer HealthCare

- Bristol-Myers Squibb

- Valeant Pharmaceuticals

- Endo Pharmaceuticals

- Foresee Pharmaceuticals

- Merck

- Novartis

- Advaxis

- Teva Pharmaceutical Industries

- Urologixs

- Agennix

- ANI Pharmaceuticals

- BHR Pharma

- Boehringer Ingelheim

- Sanpower Group

- Eisai

- Ferring

- IO THERAPEUTICS

- LIDDS

- Madrigal Pharmaceuticals

- Nymox Pharmaceutical

- Spectrum Pharmaceuticals

- Takeda Pharmaceuticals

Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Report 2021

Table of Contents
1 Benign Prostatic Hyperplasia (BPH) Medication Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Medication Product Scope
1.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2016 & 2021 & 2027)
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts (2016-2027)
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price Trends (2016-2027)
2 Benign Prostatic Hyperplasia (BPH) Medication Estimates and Forecasts by Region
2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2016-2021)
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2016-2021)
2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2016-2027)
2.4.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2016-2027)
2.4.3 China Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2016-2027)
2.4.4 Japan Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2016-2027)
2.4.6 India Benign Prostatic Hyperplasia (BPH) Medication Estimates and Projections (2016-2027)
3 Global Benign Prostatic Hyperplasia (BPH) Medication Competition Landscape by Players
3.1 Global Top Benign Prostatic Hyperplasia (BPH) Medication Players by Sales (2016-2021)
3.2 Global Top Benign Prostatic Hyperplasia (BPH) Medication Players by Revenue (2016-2021)
3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2020)
3.4 Global Benign Prostatic Hyperplasia (BPH) Medication Average Price by Company (2016-2021)
3.5 Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Review by Type (2016-2021)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2016-2021)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2016-2021)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2022-2027)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Type (2022-2027)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Type (2022-2027)
5 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Historic Market Review by Application (2016-2021)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2016-2021)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2016-2021)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2016-2021)
5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2022-2027)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Application (2022-2027)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price Forecast by Application (2022-2027)
6 North America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
6.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Company
6.1.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2016-2021)
6.1.2 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021)
6.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type
6.2.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2016-2021)
6.2.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2022-2027)
6.3 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application
6.3.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application (2016-2021)
6.3.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application (2022-2027)
7 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
7.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Company
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2016-2021)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type
7.2.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2016-2021)
7.2.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2022-2027)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application
7.3.1 Europe 142 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 142 Sales Breakdown by Application (2022-2027)
8 China Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
8.1 China Benign Prostatic Hyperplasia (BPH) Medication Sales by Company
8.1.1 China Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2016-2021)
8.1.2 China Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021)
8.2 China Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type
8.2.1 China Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2016-2021)
8.2.2 China Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2022-2027)
8.3 China Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application
8.3.1 China 315 Sales Breakdown by Application (2016-2021)
8.3.2 China 315 Sales Breakdown by Application (2022-2027)
9 Japan Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
9.1 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales by Company
9.1.1 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2016-2021)
9.1.2 Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021)
9.2 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type
9.2.1 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2016-2021)
9.2.2 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2022-2027)
9.3 Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
10.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales by Company
10.1.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2016-2021)
10.1.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021)
10.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type
10.2.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application
10.3.1 Southeast Asia KG Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia KG Sales Breakdown by Application (2022-2027)
11 India Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures
11.1 India Benign Prostatic Hyperplasia (BPH) Medication Sales by Company
11.1.1 India Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2016-2021)
11.1.2 India Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021)
11.2 India Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type
11.2.1 India Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2016-2021)
11.2.2 India Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Type (2022-2027)
11.3 India Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application
11.3.1 India Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application (2016-2021)
11.3.2 India Benign Prostatic Hyperplasia (BPH) Medication Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Benign Prostatic Hyperplasia (BPH) Medication Business
12.1 Astellas Pharma
12.1.1 Astellas Pharma Corporation Information
12.1.2 Astellas Pharma Business Overview
12.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.1.5 Astellas Pharma Recent Development
12.2 Eli Lilly
12.2.1 Eli Lilly Corporation Information
12.2.2 Eli Lilly Business Overview
12.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.2.5 Eli Lilly Recent Development
12.3 GlaxoSmithKline
12.3.1 GlaxoSmithKline Corporation Information
12.3.2 GlaxoSmithKline Business Overview
12.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.3.5 GlaxoSmithKline Recent Development
12.4 Sanofi
12.4.1 Sanofi Corporation Information
12.4.2 Sanofi Business Overview
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.4.5 Sanofi Recent Development
12.5 ADC Therapeutics
12.5.1 ADC Therapeutics Corporation Information
12.5.2 ADC Therapeutics Business Overview
12.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.5.4 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.5.5 ADC Therapeutics Recent Development
12.6 Bayer HealthCare
12.6.1 Bayer HealthCare Corporation Information
12.6.2 Bayer HealthCare Business Overview
12.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.6.5 Bayer HealthCare Recent Development
12.7 Bristol-Myers Squibb
12.7.1 Bristol-Myers Squibb Corporation Information
12.7.2 Bristol-Myers Squibb Business Overview
12.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.7.5 Bristol-Myers Squibb Recent Development
12.8 Valeant Pharmaceuticals
12.8.1 Valeant Pharmaceuticals Corporation Information
12.8.2 Valeant Pharmaceuticals Business Overview
12.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.8.5 Valeant Pharmaceuticals Recent Development
12.9 Endo Pharmaceuticals
12.9.1 Endo Pharmaceuticals Corporation Information
12.9.2 Endo Pharmaceuticals Business Overview
12.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.9.5 Endo Pharmaceuticals Recent Development
12.10 Foresee Pharmaceuticals
12.10.1 Foresee Pharmaceuticals Corporation Information
12.10.2 Foresee Pharmaceuticals Business Overview
12.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.10.5 Foresee Pharmaceuticals Recent Development
12.11 Merck
12.11.1 Merck Corporation Information
12.11.2 Merck Business Overview
12.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Merck Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.11.5 Merck Recent Development
12.12 Novartis
12.12.1 Novartis Corporation Information
12.12.2 Novartis Business Overview
12.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Novartis Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.12.5 Novartis Recent Development
12.13 Advaxis
12.13.1 Advaxis Corporation Information
12.13.2 Advaxis Business Overview
12.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.13.5 Advaxis Recent Development
12.14 Teva Pharmaceutical Industries
12.14.1 Teva Pharmaceutical Industries Corporation Information
12.14.2 Teva Pharmaceutical Industries Business Overview
12.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.14.5 Teva Pharmaceutical Industries Recent Development
12.15 Urologixs
12.15.1 Urologixs Corporation Information
12.15.2 Urologixs Business Overview
12.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.15.5 Urologixs Recent Development
12.16 Agennix
12.16.1 Agennix Corporation Information
12.16.2 Agennix Business Overview
12.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Agennix Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.16.5 Agennix Recent Development
12.17 ANI Pharmaceuticals
12.17.1 ANI Pharmaceuticals Corporation Information
12.17.2 ANI Pharmaceuticals Business Overview
12.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.17.4 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.17.5 ANI Pharmaceuticals Recent Development
12.18 BHR Pharma
12.18.1 BHR Pharma Corporation Information
12.18.2 BHR Pharma Business Overview
12.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.18.4 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.18.5 BHR Pharma Recent Development
12.19 Boehringer Ingelheim
12.19.1 Boehringer Ingelheim Corporation Information
12.19.2 Boehringer Ingelheim Business Overview
12.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.19.4 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.19.5 Boehringer Ingelheim Recent Development
12.20 Sanpower Group
12.20.1 Sanpower Group Corporation Information
12.20.2 Sanpower Group Business Overview
12.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.20.4 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.20.5 Sanpower Group Recent Development
12.21 Eisai
12.21.1 Eisai Corporation Information
12.21.2 Eisai Business Overview
12.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.21.4 Eisai Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.21.5 Eisai Recent Development
12.22 Ferring
12.22.1 Ferring Corporation Information
12.22.2 Ferring Business Overview
12.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.22.4 Ferring Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.22.5 Ferring Recent Development
12.23 IO THERAPEUTICS
12.23.1 IO THERAPEUTICS Corporation Information
12.23.2 IO THERAPEUTICS Business Overview
12.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.23.4 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.23.5 IO THERAPEUTICS Recent Development
12.24 LIDDS
12.24.1 LIDDS Corporation Information
12.24.2 LIDDS Business Overview
12.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.24.4 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.24.5 LIDDS Recent Development
12.25 Madrigal Pharmaceuticals
12.25.1 Madrigal Pharmaceuticals Corporation Information
12.25.2 Madrigal Pharmaceuticals Business Overview
12.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.25.4 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.25.5 Madrigal Pharmaceuticals Recent Development
12.26 Nymox Pharmaceutical
12.26.1 Nymox Pharmaceutical Corporation Information
12.26.2 Nymox Pharmaceutical Business Overview
12.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.26.4 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.26.5 Nymox Pharmaceutical Recent Development
12.27 Spectrum Pharmaceuticals
12.27.1 Spectrum Pharmaceuticals Corporation Information
12.27.2 Spectrum Pharmaceuticals Business Overview
12.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.27.4 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.27.5 Spectrum Pharmaceuticals Recent Development
12.28 Takeda Pharmaceuticals
12.28.1 Takeda Pharmaceuticals Corporation Information
12.28.2 Takeda Pharmaceuticals Business Overview
12.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2016-2021)
12.28.4 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Products Offered
12.28.5 Takeda Pharmaceuticals Recent Development
13 Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Cost Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Medication Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
13.4 Benign Prostatic Hyperplasia (BPH) Medication Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors List
14.3 Benign Prostatic Hyperplasia (BPH) Medication Customers
15 Market Dynamics
15.1 Benign Prostatic Hyperplasia (BPH) Medication Market Trends
15.2 Benign Prostatic Hyperplasia (BPH) Medication Drivers
15.3 Benign Prostatic Hyperplasia (BPH) Medication Market Challenges
15.4 Benign Prostatic Hyperplasia (BPH) Medication Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Medication Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Region (2016-2021)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2016-2021)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Region (2016-2021)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) Forecast by Region (2022-2027)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share Forecast by Region (2022-2027)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) of Key Companies (2016-2021)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Company (2016-2021)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Company (2016-2021)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2020)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Average Price (USD/KG) of Key Company (2016-2021)
Table 18. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Sites and Area Served
Table 19. Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2016-2021)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Type (2016-2021)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Type (2016-2021)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Type (2022-2027)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Type (2022-2027)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Type (2022-2027)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2016-2021)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Application (2016-2021)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Application (2016-2021)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2022-2027)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Application (2022-2027)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Application (2022-2027)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Application (2022-2027)
Table 38. North America Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2016-2021)
Table 39. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2016-2021)
Table 40. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2016-2021)
Table 42. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2016-2021) & (KG)
Table 43. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2016-2021)
Table 44. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2022-2027) & (KG)
Table 45. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2022-2027)
Table 46. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2016-2021) & (KG)
Table 47. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2016-2021)
Table 48. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2022-2027) & (KG)
Table 49. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2022-2027)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2016-2021)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2016-2021)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2016-2021)
Table 54. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2016-2021) & (KG)
Table 55. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2016-2021)
Table 56. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2022-2027) & (KG)
Table 57. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2022-2027)
Table 58. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2016-2021) & (KG)
Table 59. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2016-2021)
Table 60. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2022-2027) & (KG)
Table 61. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2022-2027)
Table 62. China Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2016-2021)
Table 63. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2016-2021)
Table 64. China Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2016-2021)
Table 66. China Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2016-2021) & (KG)
Table 67. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2016-2021)
Table 68. China Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2022-2027) & (KG)
Table 69. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2022-2027)
Table 70. China Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2016-2021) & (KG)
Table 71. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2016-2021)
Table 72. China Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2022-2027) & (KG)
Table 73. China Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2022-2027)
Table 74. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Company (2016-2021)
Table 75. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2016-2021)
Table 76. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2016-2021)
Table 78. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2016-2021) & (KG)
Table 79. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2016-2021)
Table 80. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2022-2027) & (KG)
Table 81. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2022-2027)
Table 82. Japan Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2016-2021) & (KG)
Table 83. Japan Benign Prostatic Hyperpla
  • Global Prenatal Vitamin Ingredients Sales Market Report 2021
    Published: 11-Jun-2021        Price: US 4000 Onwards        Pages: 146
    Market Analysis and Insights: Global Prenatal Vitamin Ingredients Market The global Prenatal Vitamin Ingredients market was valued at US$ 51370 in 2020 and will reach US$ 63150 million by the end of 2027, growing at a CAGR of 3.5% during 2022-2027. Global Prenatal Vitamin Ingredients Scope and Market Size The global Prenatal Vitamin Ingredients market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants......
  • Global Specialty Supplements Sales Market Report 2021
    Published: 11-Jun-2021        Price: US 4000 Onwards        Pages: 144
    A specialty supplement is a formula that has been specially designed to support a specific structure/function application in the body - such as joint health and immune support. Some are single-ingredient products. Others are combination formulas, providing unique blends of complementary ingredients that scientific research has shown work synergistically in the body to illicit similar pharmacological effects. Market Analysis and Insights: Global Specialty Supplements Market ......
  • Global Letter Vitamins Sales Market Report 2021
    Published: 11-Jun-2021        Price: US 4000 Onwards        Pages: 148
    A vitamin is an organic molecule (or related set of molecules) that is an essential micronutrient that an organism needs in small quantities for the proper functioning of its metabolism. Essential nutrients cannot be synthesized in the organism, either at all or not in sufficient quantities, and therefore must be obtained through the diet. Vitamin C can be synthesized by some species but not by others; it is not a vitamin in the first instance but is in the second. Market Analysis......
  • Global Curcuminoid Sales Market Report 2021
    Published: 11-Jun-2021        Price: US 4000 Onwards        Pages: 142
    Market Analysis and Insights: Global Curcuminoid Market The global Curcuminoid market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027. Global Curcuminoid Scope and Market Size The global Curcuminoid market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Curcuminoid market will be able to gain the upper hand as th......
  • Global Pet Medicine Sales Market Report 2021
    Published: 11-Jun-2021        Price: US 4000 Onwards        Pages: 136
    Well over half of the triplicate in the United States own a pet -- almost 80 million homes!Man 's best friend took a be the most iconic. But it' s been a dog, cat, horse, bird, fish, or lizard, pets need to be cared for, pet medical is required. Market Analysis and Insights: Global Pet Medicine Market The global Pet Medicine market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027. Global ......
  • Global Large Volume Parenteral (LVP) Market Insights and Forecast to 2027
    Published: 11-Jun-2021        Price: US 4900 Onwards        Pages: 148
    Large volume parenterals or LVPs (sometimes called large volume injections) are aqueous solutions usually supplied in volumes of at least 100 ml with sizes of 250 ml, 500 ml, 1000 ml, 3000 ml, and 5000 ml most common. Directions usually recommend that large quantities be administered. Parenteral preparations are sterile, solid dosage form or pyrogen-free liquids, which contain one or more number of active ingredients boxed in single or multi dose containers. They are meant to be adm......
  • Global Seaweed Powder Market Insights and Forecast to 2027
    Published: 11-Jun-2021        Price: US 4900 Onwards        Pages: 118
    Seaweed powder is made from marine natural seaweed, supplemented by a small amount of marine microalgae. Natural seaweed powder is rich in seaweed polysaccharides, mannitol, amino acids, proteins, vitamins and potassium, iron, calcium, phosphorus, iodine, selenium, cobalt and other trace elements. The global seaweed powder market is dominated by the Asia Pacific region, and North America is the second largest regional market. At present, the main manufacturers of seaweed powder are ......
  • Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Insights and Forecast to 2027
    Published: 11-Jun-2021        Price: US 4900 Onwards        Pages: 111
    Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%. Market A......
  • Global Cell Culture Protein Surface Coatings Market Insights and Forecast to 2027
    Published: 11-Jun-2021        Price: US 4900 Onwards        Pages: 115
    The cell culture protein surface coating is a technique in which the cell culture surfaces are coated with extracellular matrix or proteins components to improve the proliferation and adhesion of the cells in vitro. In the last several years, global market of Cell Culture Protein Surface Coatings developed rapidly, with an average growth rate of 13.7%. Market Analysis and Insights: Global Cell Culture Protein Surface Coatings Market The global Cell Culture Protein Su......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs